5gn5: Difference between revisions
New page: '''Unreleased structure''' The entry 5gn5 is ON HOLD Authors: Balogun, E.O., Inaoka, D.K., Shiba, T., Tsuge, T., May, B., Sato, T., Kido, Y., Takeshi, N., Aoki, T., Honma, T., Tanaka, A... |
No edit summary |
||
| (6 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of glycerol kinase from Trypanosoma brucei gambiense complexed with cumarin derivative-17== | |||
<StructureSection load='5gn5' size='340' side='right'caption='[[5gn5]], [[Resolution|resolution]] 2.85Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[5gn5]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Trypanosoma_brucei_gambiense Trypanosoma brucei gambiense]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5GN5 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5GN5 FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.85Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=6XZ:4-[[4-(4-methoxyphenyl)piperazin-1-yl]methyl]-7,8-bis(oxidanyl)chromen-2-one'>6XZ</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5gn5 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5gn5 OCA], [https://pdbe.org/5gn5 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5gn5 RCSB], [https://www.ebi.ac.uk/pdbsum/5gn5 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5gn5 ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/D3KVM3_TRYBG D3KVM3_TRYBG] | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
African trypanosomiasis, sleeping sickness in humans or nagana in animals, is a potentially fatal neglected tropical disease and a threat to 65 million human lives and 100 million small and large livestock animals in sub-Saharan Africa. Available treatments for this devastating disease are few and have limited efficacy, prompting the search for new drug candidates. Simultaneous inhibition of the trypanosomal glycerol kinase (TGK) and trypanosomal alternative oxidase (TAO) is considered a validated strategy toward the development of new drugs. Our goal is to develop a TGK-specific inhibitor for coadministration with ascofuranone (AF), the most potent TAO inhibitor. Here, we report on the identification of novel compounds with inhibitory potency against TGK. Importantly, one of these compounds (compound 17) and its derivatives (17a and 17b) killed trypanosomes even in the absence of AF. Inhibition kinetics revealed that derivative 17b is a mixed-type and competitive inhibitor for TGK and TAO, respectively. Structural data revealed the molecular basis of this dual inhibitory action, which, in our opinion, will aid in the successful development of a promising drug to treat trypanosomiasis. Although the EC50 of compound 17b against trypanosome cells was 1.77 microM, it had no effect on cultured human cells, even at 50 microM.-Balogun, E. O., Inaoka, D. K., Shiba, T., Tsuge, C., May, B., Sato, T., Kido, Y., Nara, T., Aoki, T., Honma, T., Tanaka, A., Inoue, M., Matsuoka, S., Michels, P. A. M., Watanabe, Y.-I., Moore, A. L., Harada, S., Kita, K. Discovery of trypanocidal coumarins with dual inhibition of both the glycerol kinase and alternative oxidase of Trypanosoma brucei brucei. | |||
Discovery of trypanocidal coumarins with dual inhibition of both the glycerol kinase and alternative oxidase of Trypanosoma brucei brucei.,Balogun EO, Inaoka DK, Shiba T, Tsuge C, May B, Sato T, Kido Y, Nara T, Aoki T, Honma T, Tanaka A, Inoue M, Matsuoka S, Michels PAM, Watanabe YI, Moore AL, Harada S, Kita K FASEB J. 2019 Nov;33(11):13002-13013. doi: 10.1096/fj.201901342R. Epub 2019 Sep, 16. PMID:31525300<ref>PMID:31525300</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 5gn5" style="background-color:#fffaf0;"></div> | ||
[[Category: | |||
[[Category: | ==See Also== | ||
[[Category: | *[[Glycerol kinase|Glycerol kinase]] | ||
[[Category: | == References == | ||
[[Category: | <references/> | ||
[[Category: | __TOC__ | ||
[[Category: | </StructureSection> | ||
[[Category: | [[Category: Large Structures]] | ||
[[Category: Matsuoka | [[Category: Trypanosoma brucei gambiense]] | ||
[[Category: | [[Category: Aoki T]] | ||
[[Category: | [[Category: Balogun EO]] | ||
[[Category: | [[Category: Harada S]] | ||
[[Category: | [[Category: Honma T]] | ||
[[Category: | [[Category: Inaoka DK]] | ||
[[Category: | [[Category: Inoue M]] | ||
[[Category: | [[Category: Kido Y]] | ||
[[Category: | [[Category: Kita K]] | ||
[[Category: Matsuoka S]] | |||
[[Category: May B]] | |||
[[Category: Michels PAM]] | |||
[[Category: Moore AL]] | |||
[[Category: Sato T]] | |||
[[Category: Shiba T]] | |||
[[Category: Takeshi N]] | |||
[[Category: Tanaka A]] | |||
[[Category: Tsuge T]] | |||
[[Category: Watanabe Y]] | |||
Latest revision as of 14:36, 2 August 2023
Crystal structure of glycerol kinase from Trypanosoma brucei gambiense complexed with cumarin derivative-17Crystal structure of glycerol kinase from Trypanosoma brucei gambiense complexed with cumarin derivative-17
Structural highlights
FunctionPublication Abstract from PubMedAfrican trypanosomiasis, sleeping sickness in humans or nagana in animals, is a potentially fatal neglected tropical disease and a threat to 65 million human lives and 100 million small and large livestock animals in sub-Saharan Africa. Available treatments for this devastating disease are few and have limited efficacy, prompting the search for new drug candidates. Simultaneous inhibition of the trypanosomal glycerol kinase (TGK) and trypanosomal alternative oxidase (TAO) is considered a validated strategy toward the development of new drugs. Our goal is to develop a TGK-specific inhibitor for coadministration with ascofuranone (AF), the most potent TAO inhibitor. Here, we report on the identification of novel compounds with inhibitory potency against TGK. Importantly, one of these compounds (compound 17) and its derivatives (17a and 17b) killed trypanosomes even in the absence of AF. Inhibition kinetics revealed that derivative 17b is a mixed-type and competitive inhibitor for TGK and TAO, respectively. Structural data revealed the molecular basis of this dual inhibitory action, which, in our opinion, will aid in the successful development of a promising drug to treat trypanosomiasis. Although the EC50 of compound 17b against trypanosome cells was 1.77 microM, it had no effect on cultured human cells, even at 50 microM.-Balogun, E. O., Inaoka, D. K., Shiba, T., Tsuge, C., May, B., Sato, T., Kido, Y., Nara, T., Aoki, T., Honma, T., Tanaka, A., Inoue, M., Matsuoka, S., Michels, P. A. M., Watanabe, Y.-I., Moore, A. L., Harada, S., Kita, K. Discovery of trypanocidal coumarins with dual inhibition of both the glycerol kinase and alternative oxidase of Trypanosoma brucei brucei. Discovery of trypanocidal coumarins with dual inhibition of both the glycerol kinase and alternative oxidase of Trypanosoma brucei brucei.,Balogun EO, Inaoka DK, Shiba T, Tsuge C, May B, Sato T, Kido Y, Nara T, Aoki T, Honma T, Tanaka A, Inoue M, Matsuoka S, Michels PAM, Watanabe YI, Moore AL, Harada S, Kita K FASEB J. 2019 Nov;33(11):13002-13013. doi: 10.1096/fj.201901342R. Epub 2019 Sep, 16. PMID:31525300[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||